BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schrag A, Taddei RN. Depression and Anxiety in Parkinson's Disease. Nonmotor Parkinson's: The Hidden Face - The Many Hidden Faces. Elsevier; 2017. pp. 623-55. [DOI: 10.1016/bs.irn.2017.05.024] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Liu Q, Mao Z, Tan C, Cai S, Shen Q, Wang M, Li J, Zhang L, Zhou F, Song C, Yuan J, Liu Y, Liu J, Liao H. Resting-state brain network in Parkinson’s disease with different degrees of depression. Front Neurosci 2022;16:931365. [DOI: 10.3389/fnins.2022.931365] [Reference Citation Analysis]
2 Koh MRE, Chua CY, Ng SY, Chia NS, Saffari SE, Chen RY, Choi X, Heng DL, Neo SX, Tay KY, Au WL, Tan E, Tan LC, Xu Z. Poor sleep quality is associated with fatigue and depression in early Parkinson's disease: A longitudinal study in the PALS cohort. Front Neurol 2022;13:998103. [DOI: 10.3389/fneur.2022.998103] [Reference Citation Analysis]
3 Liu Y, Ding L, Xianyu Y, Nie S, Yang J. Research on depression in Parkinson disease: A bibliometric and visual analysis of studies published during 2012-2021. Medicine (Baltimore) 2022;101:e29931. [PMID: 35945720 DOI: 10.1097/MD.0000000000029931] [Reference Citation Analysis]
4 Neganova ME, Aleksandrova YR, Sukocheva OA, Klochkov SG. Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders. Semin Cancer Biol 2022:S1044-579X(22)00155-9. [PMID: 35779712 DOI: 10.1016/j.semcancer.2022.06.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Nabizadeh F, Seyedalhosseini Z, Balabandian M, Reza Rostami M. Psychological outcomes of the COVID-19 pandemic in patients with Parkinson's disease: A systematic review. J Clin Neurosci 2022;102:101-8. [PMID: 35777112 DOI: 10.1016/j.jocn.2022.06.017] [Reference Citation Analysis]
6 Chang B, Ni C, Mei J, Xiong C, Chen P, Jiang M, Niu C. Nomogram for Predicting Depression Improvement after Deep Brain Stimulation for Parkinson’s Disease. Brain Sciences 2022;12:841. [DOI: 10.3390/brainsci12070841] [Reference Citation Analysis]
7 Paes-colli Y, Aguiar AFL, Isaac AR, Ferreira BK, Campos RMP, Trindade PMP, de Melo Reis RA, Sampaio LS. Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Front Cell Neurosci 2022;16:917164. [DOI: 10.3389/fncel.2022.917164] [Reference Citation Analysis]
8 Kim HI, Lim J, Choi HJ, Kim SH, Choi HJ. ERRγ Ligand Regulates Adult Neurogenesis and Depression-like Behavior in a LRRK2-G2019S-associated Young Female Mouse Model of Parkinson's Disease. Neurotherapeutics 2022. [PMID: 35614294 DOI: 10.1007/s13311-022-01244-5] [Reference Citation Analysis]
9 Kwok JYY, Choi EPH, Lee JJ, Lok KYW, Kwan JCY, Mok VCT, Auyeung M. Effects of Mindfulness Yoga Versus Conventional Physical Exercises on Symptom Experiences and Health-related Quality of Life in People with Parkinson's Disease: The Potential Mediating Roles of Anxiety and Depression. Ann Behav Med 2022:kaac005. [PMID: 35460239 DOI: 10.1093/abm/kaac005] [Reference Citation Analysis]
10 Zhang Y, Xu X. Chinese Herbal Medicine in the Treatment of Depression in Parkinson’s Disease: From Molecules to Systems. Front Pharmacol 2022;13:879459. [DOI: 10.3389/fphar.2022.879459] [Reference Citation Analysis]
11 Wei X, Wang Z, Zhang M, Li M, Chen Y, Lv H, Tuo H, Yang Z, Wang Z, Ba F. Brain Surface Area Alterations Correlate With Gait Impairments in Parkinson’s Disease. Front Aging Neurosci 2022;14:806026. [DOI: 10.3389/fnagi.2022.806026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Falconer R, Whitney D, Walters H, Rogers S. Prevalence of Pseudobulbar Affect (PBA) in Parkinson's Disease: An Underrecognized Patient Burden. Cureus 2021;13:e19960. [PMID: 34868793 DOI: 10.7759/cureus.19960] [Reference Citation Analysis]
13 Yao C, Niu L, Fu Y, Zhu X, Yang J, Zhao P, Sun X, Ma Y, Li S, Li J. Cognition, motor symptoms, and glycolipid metabolism in Parkinson's disease with depressive symptoms. J Neural Transm (Vienna) 2021. [PMID: 34837534 DOI: 10.1007/s00702-021-02437-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Ekimova IV, Pazi MB, Belan DV, Polonik SG, Pastukhov YF. The Chaperone Inducer U133 Eliminates Anhedonia and Prevents Neurodegeneration in Monoaminergic Emotiogenic Brain Structures in a Preclinical Model of Parkinson’s Disease in Aged Rats. J Evol Biochem Phys 2021;57:1130-41. [DOI: 10.1134/s0022093021050148] [Reference Citation Analysis]
15 Torres ERS, Stanojlovic M, Zelikowsky M, Bonsberger J, Hean S, Mulligan C, Baldauf L, Fleming S, Masliah E, Chesselet MF, Fanselow MS, Richter F. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease. Neurobiol Dis 2021;158:105478. [PMID: 34390837 DOI: 10.1016/j.nbd.2021.105478] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Cui J, Qin Y, Tian Y, Ge X, Han H, Yang Z, Yu H. Activities of daily living as a longitudinal moderator of the effect of autonomic dysfunction on anxiety and depression of Parkinson's patients. Brain Behav 2021. [PMID: 34333879 DOI: 10.1002/brb3.2297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Fearn S, Bartolomeu Pires S, Agarwal V, Roberts HC, Spreadbury J, Kipps C. The Causes and Impact of Crisis for People with Parkinson's Disease: A Patient and Carer Perspective. J Parkinsons Dis 2021. [PMID: 34250952 DOI: 10.3233/JPD-212641] [Reference Citation Analysis]
18 Morissette MP, Prior HJ, Tate RB, Wade J, Leiter JRS. Associations between concussion and risk of diagnosis of psychological and neurological disorders: a retrospective population-based cohort study. Fam Med Community Health 2020;8:e000390. [PMID: 32719017 DOI: 10.1136/fmch-2020-000390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Lyu S, Guo Y, Zhang L, Tang G, Li R, Yang J, Gao S, Li W, Liu J. Downregulation of astroglial glutamate transporter GLT-1 in the lateral habenula is associated with depressive-like behaviors in a rat model of Parkinson's disease. Neuropharmacology 2021;196:108691. [PMID: 34197892 DOI: 10.1016/j.neuropharm.2021.108691] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
20 de Chazeron I, Durif F, Lambert C, Chereau-Boudet I, Fantini ML, Marques A, Derost P, Debilly B, Brousse G, Boirie Y, Llorca PM. A case-control study investigating food addiction in Parkinson patients. Sci Rep 2021;11:10934. [PMID: 34035366 DOI: 10.1038/s41598-021-90266-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Hussein A, Guevara CA, Del Valle P, Gupta S, Benson DL, Huntley GW. Non-Motor Symptoms of Parkinson's Disease: The Neurobiology of Early Psychiatric and Cognitive Dysfunction. Neuroscientist 2021;:10738584211011979. [PMID: 33966533 DOI: 10.1177/10738584211011979] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
22 Hong CT, Tan S, Huang TW. Psychotherapy for the Treatment of Anxiety and Depression in Patients with Parkinson Disease: A Meta-Analysis of Randomized Controlled Trials. J Am Med Dir Assoc 2021:S1525-8610(21)00340-6. [PMID: 33957132 DOI: 10.1016/j.jamda.2021.03.031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Sinaeefar MJ, Saadat P, Hamidia A, Hosseini SR. Evaluation of the cognitive impairments and depressive symptoms in patients with Parkinson's disease: A case-control study from Iran. Clin Neurol Neurosurg 2021;203:106549. [PMID: 33631508 DOI: 10.1016/j.clineuro.2021.106549] [Reference Citation Analysis]
24 Gilbert R, Khemani P. Treatment of Advanced Parkinson's Disease. J Geriatr Psychiatry Neurol 2021;:891988720988904. [PMID: 33511915 DOI: 10.1177/0891988720988904] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Assogna F, Liguori C, Cravello L, Macchiusi L, Belli C, Placidi F, Pierantozzi M, Stefani A, Mercuri B, Izzi F, Caltagirone C, Mercuri NB, Pontieri FE, Spalletta G, Pellicano C. Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. J Pers Med 2021;11:51. [PMID: 33467021 DOI: 10.3390/jpm11010051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lo Buono V, Palmeri R, De Salvo S, Berenati M, Greco A, Ciurleo R, Sorbera C, Cimino V, Corallo F, Bramanti P, Marino S, Di Lorenzo G, Bonanno L. Anxiety, depression, and quality of life in Parkinson's disease: the implications of multidisciplinary treatment. Neural Regen Res 2021;16:587-90. [PMID: 32985492 DOI: 10.4103/1673-5374.293151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lyu S, Guo Y, Zhang L, Wang Y, Tang G, Li R, Yang J, Gao S, Ma B, Liu J. Blockade of GABA transporter-1 and GABA transporter-3 in the lateral habenula improves depressive-like behaviors in a rat model of Parkinson's disease. Neuropharmacology 2020;181:108369. [DOI: 10.1016/j.neuropharm.2020.108369] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Huang Y, Huang C, Zhang Q, Wu W, Sun J. Serum BDNF discriminates Parkinson's disease patients with depression from without depression and reflect motor severity and gender differences. J Neurol 2021;268:1411-8. [PMID: 33179143 DOI: 10.1007/s00415-020-10299-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
29 Bian Y, Zhao C, Lee SM. Neuroprotective Potency of Saffron Against Neuropsychiatric Diseases, Neurodegenerative Diseases, and Other Brain Disorders: From Bench to Bedside. Front Pharmacol 2020;11:579052. [PMID: 33117172 DOI: 10.3389/fphar.2020.579052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
30 Kelberman M, Keilholz S, Weinshenker D. What's That (Blue) Spot on my MRI? Multimodal Neuroimaging of the Locus Coeruleus in Neurodegenerative Disease. Front Neurosci 2020;14:583421. [PMID: 33122996 DOI: 10.3389/fnins.2020.583421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
31 Pardo M, Paul NE, Collins-Praino LE, Salamone JD, Correa M. The non-selective adenosine antagonist theophylline reverses the effects of dopamine antagonism on tremor, motor activity and effort-based decision-making. Pharmacol Biochem Behav 2020;198:173035. [PMID: 32910928 DOI: 10.1016/j.pbb.2020.173035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Jonasson SB, Rantakokko M, Franzén E, Iwarsson S, Nilsson MH. Prediction of Life Satisfaction in People with Parkinson's Disease. Parkinsons Dis 2020;2020:1561037. [PMID: 32802306 DOI: 10.1155/2020/1561037] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
33 Wändell P, Fredrikson S, Carlsson AC, Li X, Sundquist J, Sundquist K. Parkinson's Disease Among Immigrant Groups and Swedish-Born Individuals: A Cohort Study of All Adults 50 Years of Age and Older in Sweden. J Parkinsons Dis 2020;10:1133-41. [PMID: 32568106 DOI: 10.3233/JPD-201962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Kwok JYY, Choi EPH, Chau PH, Wong JYH, Fong DYT, Auyeung M. Effects of spiritual resilience on psychological distress and health-related quality of life in Chinese people with Parkinson's disease. Qual Life Res 2020;29:3065-73. [PMID: 32572757 DOI: 10.1007/s11136-020-02562-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
35 Ioakeim-Skoufa I, Poblador-Plou B, Carmona-Pírez J, Díez-Manglano J, Navickas R, Gimeno-Feliu LA, González-Rubio F, Jureviciene E, Dambrauskas L, Prados-Torres A, Gimeno-Miguel A. Multimorbidity Patterns in the General Population: Results from the EpiChron Cohort Study. Int J Environ Res Public Health 2020;17:E4242. [PMID: 32545876 DOI: 10.3390/ijerph17124242] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
36 Silverstein SM, Demmin DL, Schallek JB, Fradkin SI. Measures of Retinal Structure and Function as Biomarkers in Neurology and Psychiatry. Biomarkers in Neuropsychiatry 2020;2:100018. [DOI: 10.1016/j.bionps.2020.100018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
37 Wang S, Guo P, Feng M, Qian M, Shen X, Wang G. The efficacy of scopolamine for patients with Parkinson's disease and depression: Two case reports. Asian J Psychiatr 2020;52:102107. [PMID: 32447268 DOI: 10.1016/j.ajp.2020.102107] [Reference Citation Analysis]
38 Goldman JG, Guerra CM. Treatment of Nonmotor Symptoms Associated with Parkinson Disease. Neurologic Clinics 2020;38:269-92. [DOI: 10.1016/j.ncl.2019.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
39 Daneshvar Kakhaki R, Ostadmohammadi V, Kouchaki E, Aghadavod E, Bahmani F, Tamtaji OR, J Reiter R, Mansournia MA, Asemi Z. Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Clin Neurol Neurosurg 2020;195:105878. [PMID: 32417629 DOI: 10.1016/j.clineuro.2020.105878] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
40 Titze-de-Almeida SS, Soto-Sánchez C, Fernandez E, Koprich JB, Brotchie JM, Titze-de-Almeida R. The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease. Cells 2020;9:E841. [PMID: 32244357 DOI: 10.3390/cells9040841] [Cited by in Crossref: 11] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
41 Liang S, Yu Y, Li H, Wang Y, Cheng Y, Yang H. The Study of Subthalamic Deep Brain Stimulation for Parkinson Disease-Associated Camptocormia. Med Sci Monit 2020;26:e919682. [PMID: 32222721 DOI: 10.12659/MSM.919682] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
42 Adams JL, Myers TL, Waddell EM, Spear KL, Schneider RB. Telemedicine: A valuable tool in neurodegenerative diseases. Curr Geriatr Rep 2020;9:72-81. [PMID: 32509504 DOI: 10.1007/s13670-020-00311-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
43 Mufti S, Lafaver K. Mood Disorders in Parkinson's Disease. Psychiatric Annals 2020;50:95-9. [DOI: 10.3928/00485713-20200203-01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Ugalde-Muñiz P, Fetter-Pruneda I, Navarro L, García E, Chavarría A. Chronic Systemic Inflammation Exacerbates Neurotoxicity in a Parkinson's Disease Model. Oxid Med Cell Longev 2020;2020:4807179. [PMID: 32015787 DOI: 10.1155/2020/4807179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
45 Nagatsu T. Hypothesis: neural mechanism of psychotherapy for the treatment of Parkinson's disease: cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy? J Neural Transm (Vienna) 2020;127:273-6. [PMID: 31807951 DOI: 10.1007/s00702-019-02111-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
46 Zhu M, Zhang Y, Pan J, Fu C, Wang Y. Effect of simplified Tai Chi exercise on relieving symptoms of patients with mild to moderate Parkinson's disease. J Sports Med Phys Fitness 2020;60:282-8. [PMID: 31665879 DOI: 10.23736/S0022-4707.19.10104-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
47 Matar E, Ehgoetz Martens KA, Halliday GM, Lewis SJG. Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology. J Neurol 2020;267:380-9. [DOI: 10.1007/s00415-019-09583-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
48 Kade AK, Kravchenko SV, Trofimenko AI, Chaplygina KY, Ananeva EI, Poliakov PP, Lipatova AS. [The efficacy of tes-therapy for treatment of anxiety-like behavior and motor disorders in rats with an experimental model of parkinsonism]. Zh Nevrol Psikhiatr Im S S Korsakova 2019;119:91-6. [PMID: 31626224 DOI: 10.17116/jnevro201911909191] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Hai-jiao W, Ge T, Li-na Z, Deng C, Da X, Shan-shan C, Liu L. The efficacy of repetitive transcranial magnetic stimulation for Parkinson disease patients with depression. International Journal of Neuroscience 2020;130:19-27. [DOI: 10.1080/00207454.2018.1495632] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
50 Ray S, Agarwal P. Depression and Anxiety in Parkinson Disease. Clin Geriatr Med 2020;36:93-104. [PMID: 31733705 DOI: 10.1016/j.cger.2019.09.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
51 Kyser TL, Dourson AJ, McGuire JL, Hemmerle AM, Williams MT, Seroogy KB. Characterization of Motor and Non-Motor Behavioral Alterations in the Dj-1 (PARK7) Knockout Rat. J Mol Neurosci 2019;69:298-311. [PMID: 31250274 DOI: 10.1007/s12031-019-01358-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
52 Morgese MG, Trabace L. Monoaminergic System Modulation in Depression and Alzheimer's Disease: A New Standpoint? Front Pharmacol 2019;10:483. [PMID: 31156428 DOI: 10.3389/fphar.2019.00483] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
53 Herman T, Shema-Shiratzky S, Arie L, Giladi N, Hausdorff JM. Depressive symptoms may increase the risk of the future development of freezing of gait in patients with Parkinson's disease: Findings from a 5-year prospective study. Parkinsonism Relat Disord 2019;60:98-104. [PMID: 30236826 DOI: 10.1016/j.parkreldis.2018.09.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
54 Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis. J Eur Acad Dermatol Venereol 2018;32:1343-51. [PMID: 29222958 DOI: 10.1111/jdv.14739] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]